Targeting EphA2 suppresses hepatocellular carcinoma initiation and progression by dual inhibition of JAK1/STAT3 and AKT signaling

MLA

Hao Wang, et al. “Targeting EphA2 Suppresses Hepatocellular Carcinoma Initiation and Progression by Dual Inhibition of JAK1/STAT3 and AKT Signaling.” Cell Reports, vol. 34, no. 8, Feb. 2021. EBSCOhost, https://doi.org/10.1016/j.celrep.2021.108765.

APA

Hao Wang, Wei Hou, Aldeb Perera, Carlee Bettler, Jordan R. Beach, Xianzhong Ding, Jun Li, Mitchell F. Denning, Asha Dhanarajan, Scott J. Cotler, Cara Joyce, Jun Yin, Fowsiyo Ahmed, Lewis R. Roberts, & Wei Qiu. (2021). Targeting EphA2 suppresses hepatocellular carcinoma initiation and progression by dual inhibition of JAK1/STAT3 and AKT signaling. Cell Reports, 34(8). https://doi.org/10.1016/j.celrep.2021.108765

Chicago

Hao Wang, Wei Hou, Aldeb Perera, Carlee Bettler, Jordan R. Beach, Xianzhong Ding, Jun Li, et al. 2021. “Targeting EphA2 Suppresses Hepatocellular Carcinoma Initiation and Progression by Dual Inhibition of JAK1/STAT3 and AKT Signaling.” Cell Reports 34 (8). doi:10.1016/j.celrep.2021.108765.